Generic filters
Filter by content type
Taxonomy terms

TYME – Tyme Technologies Inc


Subscribe for full access

Unlock Industry-grade Shariah Compliance for US, UK, Canada, Germany, GCC, Europe and India. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.

Get started from just $1/month


1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL

Total Analysts: 0

Company Profile

Tyme Technologies, Inc. (TYME) is a biotechnology company focused on developing cancer metabolism-based therapies for a solid tumors and hematologic cancers. TYME’s lead drug product, SM-88, is an oral investigational modified proprietary tyrosine derivative that interrupt the metabolic processes of cancer cells by breaking down the cells key defenses and leading to cell death through oxidative stress and exposure to the body’s natural immune system. TYME is focused on evaluating its preclinical pipeline of novel CMBT programs, and TYME-19 as a potential therapeutic for SARS CoV-2 diseases. Its preclinical pipeline programs SM-88i, TYME-18, TYME-T and TYME-19. The Company is also developing SM-88i, an injectable formulation of SM-88 for the treatment of multiple oncology indications and TYME-18 for the treatment of solid tumors. The Company is utilizing its metabolism-based technology and is developing TYME-19 as a potential therapeutic for coronavirus, the virus that causes Covid-19.

We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan